Search

Displaying results 7711 - 7720 of 10000 in total
  1. Drug

    ISIS 104838

    go.drugbank.com/drugs/DB16201
    Investigational

    ISIS 104838 is under investigation in clinical trial NCT00048321 (ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis).

  2. Drug

    Itolizumab

    go.drugbank.com/drugs/DB16207
    Investigational

    Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).

  3. Drug

    KAI-1678

    go.drugbank.com/drugs/DB16211
    Investigational

    KAI-1678 is under investigation in clinical trial NCT01106716 (Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia).

    Categories: Protein Kinase C-epsilon, antagonists & inhibitors
  4. Drug

    Ladostigil

    go.drugbank.com/drugs/DB16213
    Investigational

    Ladostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment).

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  5. Drug

    Landipirdine

    go.drugbank.com/drugs/DB16214
    Investigational

    Landipirdine is under investigation in clinical trial NCT02258152 (SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)).

    Categories: Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists
  6. Drug

    Lapaquistat

    go.drugbank.com/drugs/DB16215
    Investigational

    Lapaquistat is under investigation in clinical trial NCT00256178 (Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.).

    Categories: Heterocyclic Compounds, 1-Ring
  7. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    [L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE
  8. Drug

    Lerociclib

    go.drugbank.com/drugs/DB16218
    Investigational

    Lerociclib is under investigation in clinical trial NCT02983071 (G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast

  9. Drug

    Lonapegsomatropin

    go.drugbank.com/drugs/DB16220
    ApprovedInvestigational

    Lonapegsomatropin, also known as TransCon hGH or ACP 001, is a methoxypegylated prodrug of human growth hormone ([somatropin]) indicated for the treatment of children 1 year and older, weighing at least … [A237605,L36380,L36405] Unlike somatropin, which requires daily dosing, lonapegsomatropin can be administered as a single weekly dose.

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 Inducers
  10. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. … [L45206] This therapy was developed by ADC Therapeutics and its accelerated approval for relapsed or refractory B-cell lymphoma is based on promising results from the LOTIS-2 clinical trial.

    Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through A protease cleavable valine-alanine linker